SPDL1 and non-small cell lung carcinoma: Okuma et al. reported that 75% of NSCLC patients with an elevated baseline level of sPD-L1 showed progressive disease after treatment with nivolumab, with shorter time to treatment failure and reduced OS than patients with a low baseline level of sPD-L1 [26].